Source: Ergomed Group
Rare disease clinical trials present unique operational and recruitment challenges, particularly when patient populations are small, diagnoses are delayed, and treatment windows are narrow. In a Phase III study evaluating an investigational therapy for anti-GBM (Goodpasture’s) disease, success depended on identifying and enrolling eligible patients quickly while coordinating activities across a global network of sites. This case study highlights how a strategic combination of rapid site activation, expanded geographic reach, and close investigator support helped overcome these barriers.
Frequent communication between medical monitors and principal investigators enabled timely eligibility assessment and treatment decisions during the critical early weeks following hospitalization. This patient-focused operational model accelerated study startup, strengthened site engagement, and supported efficient trial execution across multiple countries. The approach delivered measurable results, including enrollment of 36 patients within the first 13 months while maintaining momentum toward overall recruitment goals.
Organizations developing therapies for rare and complex diseases can gain valuable insights into practical strategies for improving enrollment performance, enhancing collaboration, and driving clinical trial success in challenging research environments
Subscribe to access the full case study FREE!
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today
- Request Info
- Contact Details
- Company Profile
{{/if}}
{{/each}}
{{/if}}
